Powder: -20°C for 3 years | In solvent: -80°C for 1 year
XST-14 is a competitive and specific inhibitor of ULK1 (IC50: 26.6 nM).XST-14 blocks autophagy by inhibiting the phosphorylation of ULK1 downstream substrates.XST-14 induces apoptosis and inhibits the growth of HCC cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 135.00 | |
5 mg | In stock | $ 329.00 | |
10 mg | In stock | $ 489.00 | |
25 mg | In stock | $ 785.00 | |
50 mg | In stock | $ 1,120.00 | |
100 mg | In stock | $ 1,610.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 226.00 |
Description | XST-14 is a competitive and specific inhibitor of ULK1 (IC50: 26.6 nM).XST-14 blocks autophagy by inhibiting the phosphorylation of ULK1 downstream substrates.XST-14 induces apoptosis and inhibits the growth of HCC cells. |
Targets&IC50 | ULK1:26.6 nM |
In vitro | Treatment of HepG2 cells with XST-14 (5 μM) alone or in combination with sorafenib (5 μM) for 24 hours showed a synergistic effect, indicating that XST-14 in combination with sorafenib can inhibit HCC in vitro[1]. |
In vivo | BALB/c mice were treated with XST-14 (30 mg/kg, IP, every other day), sorafenib (30 mg/kg, P.O), or a combination of sorafenib (30 mg/kg, P.O) and XST-14 (30 mg/kg, IP) for 2 weeks. The results indicate that XST-14 exhibits favorable drug metabolism and pharmacokinetic (DMPK) properties, with no significant toxicity observed on liver/kidney function or body weight. |
Molecular Weight | 291.34 |
Formula | C16H21NO4 |
CAS No. | 2607143-50-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (274.59 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
XST-14 2607143-50-8 Apoptosis Autophagy inhibitor inhibit